Analysts Conflicted on These Healthcare Names: Cue Biopharma (CUE) and Mirati Therapeutics (MRTX)

Analysts have been eager to weigh in on the Healthcare sector with new ratings on Cue Biopharma (CUE – Research Report) and Mirati Therapeutics (MRTX – Research Report).

Cue Biopharma (CUE)

In a report released today, Reni Benjamin from JMP Securities reiterated a Buy rating on Cue Biopharma, with a price target of $15.00. The company’s shares closed last Monday at $2.55.

According to TipRanks.com, Benjamin ‘s ranking currently consits of 0 on a 0-5 ranking scale, with an average return of -16.2% and a 26.5% success rate. Benjamin covers the Healthcare sector, focusing on stocks such as Deciphera Pharmaceuticals, Iovance Biotherapeutics, and Bicycle Therapeutics.

The word on The Street in general, suggests a Strong Buy analyst consensus rating for Cue Biopharma with a $11.00 average price target, representing a 329.7% upside. In a report released yesterday, Piper Sandler also reiterated a Buy rating on the stock with a $8.00 price target.

See today’s best-performing stocks on TipRanks >>

Mirati Therapeutics (MRTX)

In a report released today, Silvan Tuerkcan from JMP Securities maintained a Hold rating on Mirati Therapeutics. The company’s shares closed last Monday at $56.27.

According to TipRanks.com, Tuerkcan is a 1-star analyst with an average return of -2.4% and a 33.2% success rate. Tuerkcan covers the Healthcare sector, focusing on stocks such as Crispr Therapeutics AG, Terns Pharmaceuticals, and Taysha Gene Therapies.

Mirati Therapeutics has an analyst consensus of Hold, with a price target consensus of $57.23, which is a 2.0% upside from current levels. In a report released yesterday, Stifel Nicolaus also downgraded the stock to Hold with a $59.00 price target.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Read More on CUE:

• Cue Biopharma presents data from Phase 1 trials of CUE-101
• Cue Biopharma Presents New Positive Data from Phase 1 Trials of CUE-101 in Head and Neck Cancer and CUE-102 in Wilms’ Tumor 1 Positive Cancers at SITC 2023
• Cue Biopharma Announces Upcoming Scientific Presentations at the Society for Immunotherapy of Cancer’s (SITC) 38th Annual Meeting
• Cue Biopharma completes patient enrollment in Phase 1b study of CUE-101
• Cue Biopharma Announces Completion of Patient Enrollment in Phase 1b Study of CUE-101 in Combination with KEYTRUDA®